Search

Your search keyword '"Gangneux, J.-P."' showing total 303 results
Start Over Author "Gangneux, J.-P."
303 results on '"Gangneux, J.-P."'

1. P229 Do CFTR modulators interfere with microbiological diagnosis?

Author

Héry-Arnaud, G., primary, Vallet, S., additional, Bougnoux, M.-E., additional, Cardot-Martin, E., additional, Cassaing, S., additional, Chesnay, A., additional, Crémet, L., additional, Doléans-Jordheim, A., additional, Dupont, C., additional, Ferroni, A., additional, Gangneux, J.-P., additional, Garnier, F., additional, Guet-Revillet, H., additional, Guillard, T., additional, Handala, L., additional, Herrmann, J.-L., additional, Jeannot, K., additional, Lachaud, L., additional, Le Gal, S., additional, Lehours, P., additional, Mainardi, J.-L., additional, Millon, L., additional, Piau, C., additional, Persat, F., additional, Villena, I., additional, Yéra, H., additional, Velo-Suarez, L., additional, and Delhaes, L., additional

Published
2024
Full Text
View/download PDF

2. Antifungal susceptibility testing practices in mycology laboratories in France, 2018

Author

Bellanger, A.-P., Persat, F., Foulet, F., Bonnal, C., Accoceberry, I., Angebault, C., Angoulvant, A., Augereau, O., Bailly, E., Bert, F., Bonhomme, J., Bouchara, J.-P., Bougnoux, M.-E., Bourdeau, P., Bouteille, B., Brun, S., Brunet, K., Camin-Ravenne, A.-M., Cassaing, S., Chouaki, T., Cornet, M., Costa, D., Desbois, N., Dorin, J., Fekkar, A., Fiacre, A., Fréalle, E., Gangneux, J.-P., Guillot, J., Guitard, J., Hasseine, L., Huguenin, A., Lachaud, L., Larréché, S., Lavergne, R.-A., Le Gal, S., Le Govic, Y., Letscher-Bru, V., Machouart, M., Mazars, E., Nourrisson, C., Paugam, A., Ranque, S., Risco-Castillo, V., Sasso, M., Sautour, M., Sendid, B., Senghor, Y., Botterel, F., and Dannaoui, Eric

Published
2020
Full Text
View/download PDF

4. Lyme borreliosis and other tick-borne diseases. Guidelines from the French scientific societies

Author

Gocko, X., Lenormand, C., Lemogne, C., Bouiller, K., Gehanno, J.-F., Rabaud, C., Perrot, S., Eldin, C., de Broucker, T., Roblot, F., Toubiana, J., Sellal, F., Vuillemet, F., Sordet, C., Fantin, B., Lina, G., Sobas, C., Jaulhac, B., Figoni, J., Chirouze, C., Hansmann, Y., Hentgen, V., Caumes, E., Dieudonné, M., Picone, O., Bodaghi, B., Gangneux, J.-P., Degeilh, B., Partouche, H., Saunier, A., Sotto, A., Raffetin, A., Monsuez, J.-J., Michel, C., Boulanger, N., Cathebras, P., and Tattevin, P.

Published
2019
Full Text
View/download PDF

5. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

Author

Ullmann, A.J., Aguado, J.M., Arikan-Akdagli, S., Denning, D.W., Groll, A.H., Lagrou, K., Lass-Flörl, C., Lewis, R.E., Munoz, P., Verweij, P.E., Warris, A., Ader, F., Akova, M., Arendrup, M.C., Barnes, R.A., Beigelman-Aubry, C., Blot, S., Bouza, E., Brüggemann, R.J.M., Buchheidt, D., Cadranel, J., Castagnola, E., Chakrabarti, A., Cuenca-Estrella, M., Dimopoulos, G., Fortun, J., Gangneux, J.-P., Garbino, J., Heinz, W.J., Herbrecht, R., Heussel, C.P., Kibbler, C.C., Klimko, N., Kullberg, B.J., Lange, C., Lehrnbecher, T., Löffler, J., Lortholary, O., Maertens, J., Marchetti, O., Meis, J.F., Pagano, L., Ribaud, P., Richardson, M., Roilides, E., Ruhnke, M., Sanguinetti, M., Sheppard, D.C., Sinkó, J., Skiada, A., Vehreschild, M.J.G.T., Viscoli, C., and Cornely, O.A.

Published
2018
Full Text
View/download PDF

6. Quelles mesures pour maîtriser le risque infectieux chez les patients immunodéprimés ? Recommandations formalisées d’experts

Author

Zahar, J.-R., Jolivet, S., Adam, H., Dananché, C., Lizon, J., Alfandari, S., Boulestreau, H., Baghdadi, N., Bay, J.-O., Bénéteau, A.-M., Bougnoux, M.-E., Brenier-Pinchart, M.-P., Dalle, J.-H., Fournier, S., Fuzibet, J.-G., Kauffmann-Lacroix, C., Le Guinche, I., Lepelletier, D., Loukili, N., Lory, A., Morvan, M., Oumedaly, R., Ribaud, P., Rohrlich, P., Vanhems, P., Aho, S., Vanjak, D., and Gangneux, J.-P.

Published
2017
Full Text
View/download PDF

13. Environmental and bioclimatic factors influencing yeasts and molds distribution along European shores

Author

Cogliati, M., Arikan-Akdagli, S., Barac, A., Bostanaru, A. C., Brito, S., Çerikçioğlu, N., Efstratiou, M. A., Ergin, Ç., Esposto, M. C., Frenkel, M., Gangneux, J. P., Gitto, A., Gonçalves, C. I., Guegan, H., Gunde-Cimerman, N., Güran, M., Jonikaitė, E., Kataržytė, M., Klingspor, L., Mares, M., Meijer, W. G., Melchers, W. J. G., Meletiadis, J., Nastasa, V., Babič, M. Novak, Ogunc, D., Ozhak, B., Prigitano, A., Ranque, S., Romanò, L., Rusu, R. O., Sabino, Raquel Filipa Pinheiro, Sampaio, A., Silva, S., Stephens, J. H., Tehupeiory-Kooreman, M., Velegraki, A., Veríssimo, Cristina, Segal, E., Brandão, J., Università degli Studi di Milano = University of Milan (UNIMI), Hacettepe University = Hacettepe Üniversitesi, University of Belgrade [Belgrade], Universitatea de Ştiinţe Agricole şi Medicină Veterinară 'Ion Ionescu de la Brad' - University of life sciences [Iasi, Romania], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), École des Hautes Études en Santé Publique [EHESP] (EHESP), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Harokopio University of Athens, Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Tel Aviv University (TAU), Universidade de Lisboa = University of Lisbon (ULISBOA), Ana Sampaio thanks to the Foundation for Science and Technology and FEDER under Programe PT2020 for financial support to CITAB (UID/AGR/04033/2020)., and Repositório da Universidade de Lisboa

Subjects
Precipitation (chemical), Settore MED/42 - Igiene Generale e Applicata, river, yeast, Molds, Spatial distribution modelling, Soil, Sand, environmental factor, Yeasts, Distribution models, Soil Pollutants, Waste Management and Disposal, Candida, Spatial distribution modeling, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], Mycosands, Modeling approach, concentration (composition), pH, Pollution, Species distribution modeling, Web database, Europe, Metals, [SDE]Environmental Sciences, Avaliação do Risco, Environmental Factors, Cadmium, Environmental Monitoring, soil pollutant, Environmental Engineering, metal, Fumigatus, Chemical and physical properties, chlorophyll a, chemistry, environmental factors, molds, sand, spatial distribution modelling, water, yeasts, Agentes Microbianos e Ambiente, Sediments, All institutes and research themes of the Radboud University Medical Center, Rivers, Lows-temperatures, Environmental factors, Environmental Chemistry, Spatial Distribution Modelling, Infecções Sistémicas e Zoonoses, Chlorophyll-a concentration, Beach, Water, soil property, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Probability distributions, Soils, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Soil datasets, bioclimatology
Abstract

© 2022 Elsevier B.V. All rights reserved., The present study employed data collected during the Mycosands survey to investigate the environmental factors influencing yeasts and molds distribution along European shores applying a species distribution modelling approach. Occurrence data were compared to climatic datasets (temperature, precipitation, and solar radiation), soil datasets (chemical and physical properties), and water datasets (temperature, salinity, and chlorophyll-a concentration) downloaded from web databases. Analyses were performed by MaxEnt software. Results suggested a different probability of distribution of yeasts and molds along European shores. Yeasts seem to tolerate low temperatures better during winter than molds and this reflects a higher suitability for the Northern European coasts. This difference is more evident considering suitability in waters. Both distributions of molds and yeasts are influenced by basic soil pH, probably because acidic soils are more favorable to bacterial growth. Soils with high nitrogen concentrations are not suitable for fungal growth, which, in contrast, are optimal for plant growth, favored by this environment. Finally, molds show affinity with soil rich in nickel and yeasts with soils rich in cadmium resulting in a distribution mainly at the mouths of European rivers or lagoons, where these metals accumulate in river sediments., Ana Sampaio thanks to the Foundation for Science and Technology and FEDER under Programe PT2020 for financial support to CITAB (UID/AGR/04033/2020)

Published
2022

14. Recommandations sur l’utilisation des nouveaux outils diagnostiques étiologiques des infections respiratoires basses de l’enfant de plus de trois mois

Author

Dubus, J.-C., Delacourt, C., Marguet, C., Houdouin, V., Pouessel, G., Angoulvant, F., Brouard, J., Derelle, J., Fayon, M., Ferroni, A., Gangneux, J.-P., Hau, I., Le Bourgeois, M., Lorrot, M., Menotti, J., Nathan, N., Vabret, A., Wallet, F., Bonacorsi, S., Cohen, R., de Blic, J., Deschildre, A., Gandemer, V., Pin, I., Labbe, A., Le Roux, P., Martinot, A., and Rammaert, B.

Published
2014
Full Text
View/download PDF

15. Impact of Guideline adherence on outcome in Candidemia : Results from the ECMM Candida III multinational European study

Author

Egger, M., Honigl, M., Salmanton--Garcia, J., Arendrup, M. C., Kohler, P., Gangneux, J. P., Bicanic, T., Arikan--Akdagli, S., Lass-Florl, C., Prattes, J., Willinger, B., Steinmann, J., Seufert, R., Trauth, J., Scharmann, U., Khanna, N., Adam, K. M., Meijer, E., and Oliver Cornely

Subjects
Medizin
Abstract

Objectives: The European Confederation of Medical Mycology (ECMM) collected data on epidemiology, risk factors, treatment, and outcomes of culture proven candidemia across Europe in order to assess how adherence to guideline recommendations correlate with outcome Methods: Each participating hospital included the first ~10 culture proven IC cases after 01-Jul-18 and entered data into the ECMM Candida III database on the FungiScope™ platform. EQUAL Candida Scores reflecting adherence to Guideline recommendations were assessed. Results: A total of 632 Candidemia cases were included from 64 institutions in 20 European countries. Overall mortality was 45% (286/632), and hospital stay was prolonged (median 2 days), for completion of parenteral therapy only, in 16% (100/621) of patients. EQUAL Candida Score was evaluable for 589 cases with candidemia. Candida scores correlated significantly with duration of hospitalization (r = 0.442; p

Published
2022

18. Cerebral aspergillosis in the era of new antifungals: The CEREALS national cohort study Nationwide CEREbral Aspergillosis Lesional study (CEREALS)

Author

Serris, A., primary, Benzakoun, J., additional, Danion, F., additional, Porcher, R., additional, Sonneville, R., additional, Wolff, M., additional, Kremer, S., additional, Letscher-Bru, V, additional, Fekkar, A, additional, Hekimian, G., additional, Pourcher, V., additional, Bougnoux, M-E., additional, Poirée, S., additional, Ader, F., additional, Persat, F., additional, Cotton, Francois, additional, Tattevin, Pierre, additional, Gangneux, J.-P., additional, Lelièvre, L., additional, Cassaing, S., additional, Bonneville, Fabrice, additional, Houze, S., additional, Bretagne, Stephane, additional, Herbrecht, R., additional, Lortholary, O., additional, Naggara, O., additional, and Lanternier, F., additional

Published
2022
Full Text
View/download PDF

22. Nodules ulcérés du visage révélant un lymphome T cutané épidermotrope CD8+ cytotoxique agressif

Author

Rolland, M., Dinulescu, M., Saillard, C., Battistella, M., Le Gall, F., Lhomme, F., Gangneux, J.-P., Dupuy, A., Adamski, H., Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes], Service d’Hématologie Clinique [Rennes], Service de Parasitologie-Mycologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Lymphome T cutané épidermotrope CD8+ cytotoxique, [SDV]Life Sciences [q-bio], Lymphome T cutané épidermotrope CD8+ agressif, Leishmaniose
Abstract

National audience; Introduction :Le lymphome cutané T épidermotrope CD8+ cytotoxique agressif est une affection rare dont le pronostic est redoutable. Nous rapportons un nouveau cas, original par le caractère affichant des lésions faciales et par sa difficulté diagnostique.Observation :Une femme de 39 ans était adressée pour des nodules ulcérés du visage évoluant depuis 8 semaines. Elle avait séjourné 3 mois auparavant à Djerba (Tunisie). Le premier bilan n’avait pas retrouvé d’anomalie significative sur les examens sanguins usuels et la biopsie cutanée montrait un infiltrat lymphocytaire sans orientation spécifique. Les divers traitements (amoxicilline/acide clavulanique, valaciclovir, corticothérapie, colchicine, doxycycline) étaient inefficaces. Une recherche de leishmaniose par PCR sur prélèvement cutané était positive, mais l’examen direct et la culture étaient négatifs. Un traitement par antimoniate de méglumine était débuté. Les nouvelles biopsies cutanées retrouvaient un infiltrat lymphocytaire en faveur d’un lymphome T épidermotrope CD8+ cytotoxique. La tomographie par émission de positons objectivait de multiples hypermétabolismes au niveau de la face et plusieurs formations ganglionnaires diffuses. L’antimoine était stoppé. Une polychimiothérapie permettait d’obtenir une rémission complète.Conclusion :Le lymphome cutané T épidermotrope CD8+ cytotoxique est caractérisé par un début très rapide et par des nodules ulcérés à disposition acrale, Dans notre observation, la PCR leishmaniose, qui s’est révélée être faussement positive, a été un facteur de confusion dans la démarche diagnostique. En raison du caractère agressif du lymphome avec dissémination viscérale précoce, une polychimiothérapie ainsi qu’une greffe de moelle sont indiquées.

Published
2020

23. Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to Categorize Aspergillosis in ICU Patients? A Monocentric Experience

Author

Gangneux, J-P, Reizine, Florian, Guegan, Hélène, Pinceaux, Kieran, Le Balch, Pierre, Prat, Emilie, Pelletier, Romain, Belaz, Sorya, Le Souhaitier, Mathieu, Le Tulzo, Yves, Seguin, Philippe, Lederlin, Mathieu, Tadié, Jean-Marc, Robert-Gangneux, Florence, CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
invasive aspergillosis, Sars-CoV-2, COVID-19, Article, probable, Aspergillus, PCR, putative, classification, lcsh:Biology (General), [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, galactomannan, ICU, lcsh:QH301-705.5
Abstract

(1) Background: The diagnosis of invasive aspergillosis (IA) in an intensive care unit (ICU)remains a challenge and the COVID-19 epidemic makes it even harder. Here, we evaluatedAspergillus PCR input to help classifying IA in SARS-CoV-2-infected patients. (2) Methods: 45COVID-19 patients were prospectively monitored twice weekly for Aspergillus markers and anti-Aspergillus serology. We evaluated the concordance between (&Iota, ) Aspergillus PCR and culture inrespiratory samples, and (&Iota, &Iota, ) blood PCR and serum galactomannan. Patients were classified asputative/proven/colonized using AspICU algorithm and two other methods. (3) Results: Theconcordance of techniques applied on respiratory and blood samples was moderate (kappa = 0.58and kappa = 0.63, respectively), with a higher sensitivity of PCR. According to AspICU, 9/45 patientswere classified as putative IA. When incorporating PCR results, 15 were putative IA because theymet all criteria, probably with a lack of specificity in the context of COVID-19. Using a modifiedAspICU algorithm, eight patients were classified as colonized and seven as putative IA. (4)Conclusion: An appreciation of the fungal burden using PCR and Aspergillus serology was addedto propose a modified AspICU algorithm. This proof of concept seemed relevant, as it was inagreement with the outcome of patients, but will need validation in larger cohorts.

Published
2020

24. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey

Author

Cornillet, A., Camus, C., Nimubona, S., Gandemer, V., Tattevin, P., Belleguic, C., Chevrier, S., Meunier, C., Lebert, C., Aupee, M., Caulet-Maugendre, S., Faucheux, M., Lelong, B., Leray, E., Guiguen, C., and Gangneux, J.-P.

Subjects
Aspergillosis -- Care and treatment, Aspergillosis -- Patient outcomes, Aspergillosis -- Research, Neutropenia -- Patient outcomes, Neutropenia -- Research, Mortality -- Research, Health, Health care industry
Published
2006

25. Anaphylaxis due to anisakidosis

Author

Autier, B., primary, Stéphant, S., additional, Beusnel, C., additional, Sichel, P., additional, Belaz, S., additional, Gangneux, J.-P., additional, and Robert-Gangneux, F., additional

Published
2021
Full Text
View/download PDF

32. Borréliose de Lyme et autres maladies vectorielles à tiques. Recommandations des sociétés savantes françaises

Author

Gocko, X., Lenormand, C., Lemogne, C., Bouiller, K., Gehanno, J.-F., Rabaud, C., Perrot, S., Eldin, C., De Broucker, T., Roblot, F., Toubiana, J., Sellal, F., Vuillemet, F., Sordet, C., Fantin, B., Lina, G., Sobas, C., JAULHAC, B., Figoni, J., Chirouze, C., Hansmann, Y., Hentgen, V., Caumes, E., Dieudonné, M., Picone, O., Bodaghi, B., Gangneux, J.-P., Degeilh, B., Partouche, H., Saunier, A., Sotto, A., Raffetin, A., Monsuez, J.-J., Michel, C., Boulanger, N., Cathébras, P., Tattevin, P., CHU Rouen, Normandie Université (NU), Université Paris Descartes - Paris 5 (UPD5), Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), service de maladies infectieuses CHU J Minjoz Besancon, Hôpital Jean Minjoz, Haut Conseil de la Santé Publique, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), Service de neurologie [CH Saint Denis], Centre Hospitalier de Saint-Denis [Ile-de-France], Médecine interne [ Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital de Hautepierre [Strasbourg], Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Centre National de référence des Staphylocoques, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL), CHU Strasbourg, Service de maladies infectieuses et tropicales, Service de Pédiatrie, Centre Hospitalier de Versailles André Mignot (CHV), Centre Max Weber (CMW), Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Lumière - Lyon 2 (UL2)-Université Jean Monnet [Saint-Étienne] (UJM), Service de Parasitologie-Mycologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Estación Biológica de Doñana CSIC (SPAIN), Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes), Centre Hospitalier Intercommunal Villeneuve-Saint-Georges (CHIV), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Service des maladies infectieuses et réanimation médicale, and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou

Subjects
Borréliose de Lyme, Recommandations, Maladies à tiques, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2019

36. Immune parameters for diagnosis and treatment monitoring in invasive mold infection

Author

Jenks, J. D., Rawlings, S. A., Garcia-Vidal, C., Koehler, P., Mercier, T., Prattes, J., Lass-Florl, C., Martin-Gomez, M. T., Buchheidt, D., Pagano, Livio, Gangneux, J. -P., van de Veerdonk, F. L., Netea, M. G., Carvalho, A., Hoenigl, M., Pagano L. (ORCID:0000-0001-8287-928X), Jenks, J. D., Rawlings, S. A., Garcia-Vidal, C., Koehler, P., Mercier, T., Prattes, J., Lass-Florl, C., Martin-Gomez, M. T., Buchheidt, D., Pagano, Livio, Gangneux, J. -P., van de Veerdonk, F. L., Netea, M. G., Carvalho, A., Hoenigl, M., and Pagano L. (ORCID:0000-0001-8287-928X)

Abstract

Infections caused by invasive molds, including Aspergillus spp., can be difficult to diagnose and remain associated with high morbidity and mortality. Thus, early diagnosis and targeted systemic antifungal treatment remains the most important predictive factor for a successful outcome in immunocompromised individuals with invasive mold infections. Diagnosis remains difficult due to low sensitivities of diagnostic tests including culture and other mycological tests for mold pathogens, particularly in patients on mold-active antifungal prophylaxis. As a result, antifungal treatment is rarely targeted and reliable markers for treatment monitoring and outcome prediction are missing. Thus, there is a need for improved markers to diagnose invasive mold infections, monitor response to treatment, and assist in determining when antifungal therapy should be escalated, switched, or can be stopped. This review focuses on the role of immunologic markers and specifically cytokines in diagnosis and treatment monitoring of invasive mold infections.

Published
2019

39. Safety study and therapeutic drug monitoring of the oral tablet formulation of posaconazole in patients with haematological malignancies

Author

Lemaitre, Florian, Le Guillou, Adrien, Pugliese, Pascal, Raffi, François, Cuzin, Lise, Katlama, Christine, Allavena, Clotilde, Dramé, Moustapha, Cotte, Laurent, Bani-Sadr, Firouzé, Orticoni, M, Soavi, M, Luquet- Besson, I, Ressiot, E, Carta- Padovani, M, Ducassou, M, Bertone, H, Galie, S, Galinier, A., Monclar, M, Ritleng, A, Ivanova, A., Blanco-Betancourt, C, Lions, C., Poizot-Martin, I., Dhiver, C, Saadia Mokhtari, M, Menard, A., Tissot Dupont, H, Toméi, C, Meddeb, L., Belkhir, A., Ravaux, I., Alvarez, M., Biezunski, N, Debard, A., Delpierre, C, Lansalot, P, Lelievre, L., Martin-Blondel, G., Piffaut, M, Porte, L., Saune, K, Delobel, P., Breaud, S., Ceppi, C, Chirio, D, Cua, E, Dellamonica, P., Demonchy, E, De Monte, A, Durant, J., Etienne, C, Ferrando, S, Garraffo, R, Michelangeli, C, Mondain, V., Bernaud, C, Billaud, E., Biron, C, Bonnet, B, Bouchez, S, Boutoille, D., Brunet-Cartier, C, Deschanvres, C, Gaborit, B., Hall, N, Le Turnier, P., Morineau, P, Reliquet, V., Sécher, S, Cavellec, M, Soria, A., Ferre, V., André-Garnier, E., Rodallec, A., Lefebvre, M, Grossi, O, Aubry, O., Amazzough, K., Benabdelmoumen, G, Bossi, P, Cessot, G, Charlier, C., Consigny, P, Danion, F., Dureault, A, Duvivier, C., Goesch, J, Guery, R., Henry, B., Jidar, K, Lanternier, F., Loubet, P., Lortholary, O., Louisin, C, Lourenco, J, Parize, P., Pilmis, B., Touam, F, Valantin, M, Tubiana, R., Agher, R, Seang, S, Schneider, L, PaLich, R, Blanc, C, Cabié, André, Abel, S., Pierre-François, S, Pasquier, J., Guitteaud, K, Turmel, J, Illiaquer, M, Fischer, P., Partisani, M., Cheneau, C., Priester, M, Batard, M, Bernard-Henry, C, de Mautort, E, Fafi-Kremer, S., Rey, D., Chirouze, C., Gardiennet, Q, Berger, J, N’Guyen, Y, Lambert, D., Hentzien, M., Lebrun, D., Brunet, A, Kmiec, I, Brodard, V, Chidiac, C., Ferry, T., Ader, F., Biron, F., Boibieux, A., Miailhes, P., Perpoint, T., Schlienger, I, Lippmann, J, Braun, E, Koffi, J, Longuet, C., Guéripel, V, Augustin-Normand, C, Brochier, C, Degroodt, S, Atoui, N, Le Moing, V., Makinson, A., Meftah, N., de Boever, C Merle, Montes, B, Montoya Ferrer, A, Reynes, J., Andre, M., Boyer, L, Bouillon, M, Delestan, M, May, T, Hocqueloux, L, Prazuck, T., Gubavu, C, Sève, A, Maka, A, Boulard, C., Thomas, G, Cheret, A, Goujard, C, Quertainmont, Y, Teicher, E., Lerolle, N., Deradji, O, Barrail-Tran, A, Landman, R, Joly, V, Rioux, C., Lariven, S, gervais, a, Lescure, F., Matheron, S., Louni, F, Godard, C, Julia, Z, Chansombat, M, Rahli, D, Mackoumbou-Nkouka, C, Charpentier, c, Descamps, D., Peytavin, G., Yazdanpanah, Y., Tattevin, P., Revest, M., Souala, F., Baldeyrou, M., Patrat-Delon, S, Chapplain, J, Bénézit, F., Dupont, M., Poinot, M., MAILLARD, A, Pronier, C., Guennoun, C, Poisson-Vanier, M, Jovelin, T., Sinteff, J, Arvieux, C, Botelho-Nevers, E., Gagneux-Brunon, A., Frésard, A., Lucht, F., Ajana, F, Aïssi, E, Alcaraz, I, Baclet, V, Bocket, L, Boucher, A, Choisy, P, Huleux, T., Lafon-Desmurs, B., Meybeck, A, Pradier, M, Robineau, O, Viget, N, Valette, M., Hoen, B., Lamaury, I, Fabre, I, Curlier, E, Ouissa, R, Schepers, K, Herrmann-Storck, C, Dournon, N, Merrien, D, Perré, P., Guimard, T, Bollangier, O, Leautez, S, Morrier, M, Boglione-Kerrien, C., Picard, S., Tron, C., Nimubona, S., Gangneux, J.-P., Lalanne, S., Lemaître, F., Bellissant, E., Verdier, M.-C., Petitcollin, A., Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Nice (CHU Nice), Service des maladies infectieuses et tropicales [CHU Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Immunité et Infection, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de maladies infectieuses et tropicales [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Reims (CHU Reims), Service de Maladies Infectieuses et Tropicales [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Hôpital Sainte-Marguerite [CHU - APHM] (Hôpitaux Sud ), DDSIS 76, Institut national de recherche et de sécurité (Vandoeuvre lès Nancy) (INRS ( Vandoeuvre lès Nancy)), Service des Maladies Infectieuses et Tropicales [Hôpital de la Conception] (SMIT), Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), Laboratoire de Physique et Chimie Quantique, Université Mouloud Mamerri, Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Assistance Publique - Hôpitaux de Marseille (APHM), Département de Physique Nucléaire (ex SPhN) (DPHN), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Génomique métabolique (UMR 8030), Genoscope - Centre national de séquençage [Evry] (GENOSCOPE), Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Fondamentale (CEA) (DRF (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Université d'Évry-Val-d'Essonne (UEVE)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Institut des Matériaux, de Microélectronique et des Nanosciences de Provence (IM2NP), Aix Marseille Université (AMU)-Université de Toulon (UTLN)-Centre National de la Recherche Scientifique (CNRS), Département Etude des Réacteurs (DER), CEA-Direction de l'Energie Nucléaire (CEA-DEN), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Hopital l'Archet, Centre d'Information et de Soins de I'Immunodéficience Humaine (CISIH). Hôpital l'Archet 1, Hôpital l'Archet, CHU Nice [Cimiez], Hôpital Cimiez [Nice] (CHU), Centre de résonance magnétique biologique et médicale (CRMBM), Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre d'Immunologie et de Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Hôtel-Dieu de Nantes, Service de virologie [CHU Nantes], Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Science et Technologie du Lait et de l'Oeuf (STLO), AGROCAMPUS OUEST-Institut National de la Recherche Agronomique (INRA), Institut des Sciences du Mouvement Etienne Jules Marey (ISM), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Université Paris Descartes - Paris 5 (UPD5), Institut de Physique du Globe de Paris (IPGP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut national des sciences de l'Univers (INSU - CNRS)-IPG PARIS-Université Paris Diderot - Paris 7 (UPD7)-Université de La Réunion (UR)-Centre National de la Recherche Scientifique (CNRS), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses [CHU Pitié-Salêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Système membranaires, photobiologie, stress et détoxication (SMPSD), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Weill Cornell Medicine [Qatar], Institut Rayonnement Matière de Saclay (IRAMIS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Institut de pharmacologie moléculaire et cellulaire (IPMC), Université Nice Sophia Antipolis (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Transplantation et Immunologie (U1064 Inserm - CRTI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Laboratoire de Virologie [Strasbourg], GEOMA, Université de Vigo, Universidate de Vigo, Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Laboratoire d'aérologie (LA), Centre National de la Recherche Scientifique (CNRS)-Observatoire Midi-Pyrénées (OMP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Service des Maladies Infectieuses, Groupement Hospitalier Nord, Hospices Civils de Lyon, Lyon, France, parent, Pathogénie des Staphylocoques – Staphylococcal Pathogenesis, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hosp Civils Lyon, Serv Malad Infect, Lyon, France, Equipe 15, Centre de Recherche en Cancérologie de Lyon (CRCL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), Faculté des Mathématiques et des Sciences de la Matière, Université Kasdi Merbah Ouargla, Laboratoire de Géochimie Isotopique Environnementale (GIS) / Université de Nîmes (GIS), Université de Nîmes (UNIMES)-Centre National de la Recherche Scientifique (CNRS), CHU UCL Namur, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bicêtre, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et tropicales, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre d'Etudes Lasers Intenses et Applications (CELIA), Université de Bordeaux (UB)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Centre National de la Recherche Scientifique (CNRS), Pharmacie de l'Hôpital Bichat, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Service des maladies infectieuses et réanimation médicale, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Les Hôpitaux Universitaires de Strasbourg (HUS), Service de pneumologie, Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Unité des Rickettsies et pathogènes émergents (URPE), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Etienne, University Hospital and University Jean Monnet, Centre Hospitalier Tourcoing, CHU de Fort de France, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Laboratoire de Génie des Procédés et Matériaux - EA 4038 (LGPM), CentraleSupélec, Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
0301 basic medicine, Male, Cancer Research, Posaconazole, Antifungal Agents, [SDV]Life Sciences [q-bio], Administration, Oral, Dat’AIDS cohort, Pharmacology, 030226 pharmacology & pharmacy, Gastroenterology, 0302 clinical medicine, MESH: Drug Monitoring, Medicine, Prospective Studies, Haematological malignancies, media_common, MESH: Aged, Hematology, MESH: Middle Aged, medicine.diagnostic_test, General Medicine, Middle Aged, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, 90-90-90 target, 3. Good health, Posaconazole oral tablet, Oncology, Quartile, MESH: Young Adult, Hematologic Neoplasms, MESH: Administration, Oral, Female, Drug Monitoring, Antifungal prophylaxis, Safety, medicine.drug, Tablets, Drug, Adult, medicine.medical_specialty, media_common.quotation_subject, 030106 microbiology, Therapeutic drug monitoring, 03 medical and health sciences, Young Adult, Pharmacokinetics, Invasive fungal infections, Internal medicine, Pharmacovigilance, primary HIV infection, cascade of care, Humans, Aged, MESH: Humans, business.industry, MESH: Adult, TasP, Triazoles, MESH: Antifungal Agents, MESH: Prospective Studies, MESH: Male, MESH: Triazoles, MESH: Tablets, business, Liver function tests, MESH: Female, MESH: Hematologic Neoplasms
Abstract

International audience; PurposePosaconazole is a triazole antifungal widely used for prophylaxis of invasive fungal disease (IFI). Posaconazole tablets allow reaching higher plasma levels than the oral suspension, but safety data with this formulation in real life are scarce. This study aimed at evaluating the safety profile, the pharmacokinetic variability, and the concentration–toxicity relationship of posaconazole tablets in patients with haematological malignancies.MethodsSixty neutropenic patients treated with posaconazole tablets for prophylaxis of IFI were prospectively included in the study. Adverse drug reactions (ADR) were recorded and analyzed by the Regional Pharmacovigilance Centre to assess posaconazole implication. Blood samples were drawn once a week and plasma trough concentrations (C min) were assayed by LC–MS/MS. The rates of ADR by quartile of C min were compared.ResultsEighteen patients (30%) experienced at least one ADR attributed to posaconazole. Liver function test (LFT) abnormalities were encountered in 20% of patients and resulted in four (6.7%) treatment discontinuations. Posaconazole median (range) C min was 1.36 (< 0.1–3.44) µg/mL (inter-patient CV = 43.9%). During follow-up, 28.6% of patients had at least one concentration < 0.7 µg/mL, and 35.7% had at least one concentration > 2 µg/mL. Rates of ADR by quartile of C min were not different.ConclusionsPosaconazole was well tolerated; however, LFT abnormalities were frequent. ADR occurrence was not linked to posaconazole exposure. Because posaconazole concentrations were highly variable, TDM can be helpful to avoid underexposure to the drug and increase its efficacy in preventing IFI. Conversely, a large proportion of patients was overexposed and might have benefited of a dose reduction.

Published
2018

40. Erratum à « Borréliose de Lyme et autres maladies vectorielles à tiques. Recommandations des sociétés savantes françaises » [Med. Mal. Infect. 49 (2019) 296–317]

Author

Gocko, X., primary, Lenormand, C., additional, Lemogne, C., additional, Bouiller, K., additional, Gehanno, J.-F., additional, Rabaud, C., additional, Perrot, S., additional, Eldin, C., additional, de Broucker, T., additional, Roblot, F., additional, Toubiana, J., additional, Sellal, F., additional, Vuillemet, F., additional, Sordet, C., additional, Fantin, B., additional, Lina, G., additional, Sobas, C., additional, Jaulhac, B., additional, Figoni, J., additional, Chirouze, C., additional, Hansmann, Y., additional, Hentgen, V., additional, Caumes, E., additional, Dieudonné, M., additional, Picone, O., additional, Bodaghi, B., additional, Gangneux, J.-P., additional, Degeilh, B., additional, Partouche, H., additional, Saunier, A., additional, Sotto, A., additional, Raffetin, A., additional, Monsuez, J.-J., additional, Michel, C., additional, Boulanger, N., additional, Cathebras, P., additional, and Tattevin, P., additional

Published
2019
Full Text
View/download PDF

41. ACKNOWLEDGEMENT OF REVIEWERS

Author

Adams, NG, Adekambi, T, Afeltra, J, Aguado, J, Aires de Sousa, M, Akiyoshi, K, Al Hasan, M, Ala-Kokko, T, Albert, M, Alfandari, S, Allen, D, Allerberger, F, Almyroudis, N, Alp, E, Amin, R, Anderson-Berry, A, Andes, DR, Andremont, A, Andreu, A, Angelakis, M, Antachopoulos, C, Antoniadou, A, Arabatzis, M, Arlet, G, Arnez, M, Arnold, C, Asensio, A, Asseray, N, Ausiello, C, Avni, T, Ayling, R, Baddour, L, Baguelin, M, Bányai, K, Barbour, A, Basco, LK, Bauer, D, Bayston, R, Beall, B, Becker, K, Behr, M, Bejon, P, Belliot, G, Benito-Fernandez, J, Benjamin, D, Benschop, K, Berencsi, G, Bergeron, MG, Bernard, K, Berner, R, Beyersmann, J, Bille, J, Bizzini, A, Bjarnsholt, T, Blanc, D, Blanco, J, Blot, S, Bohnert, J, Boillat, N, Bonomo, R, Bonten, M, Bordon, JM, Borel, N, Boschiroli, ML, Bosilkovski, M, Bosso, JA, Botelho-Nevers, E, Bou, G, Bretagne, S, Brouqui, P, Brun-Buisson, C, Brunetto, M, Bucher, H, Buchheidt, D, Buckling, A, Bulpa, P, Cambau, E, Canducci, F, Cantón, R, Capobianchi, M, Carattoli, A, Carcopino, X, Cardona-Castro, N, Carling, PC, Carrat, F, Castilla, J, Castilletti, C, Cavaco, L, Cavallo, R, Ceccherini-Silberstein, F, Centrón, D, Chappuis, F, Charrel, R, Chen, M, Chevaliez, S, Chezzi, C, Chomel, B, Chowers, M, Chryssanthou, E, Ciammaruconi, A, Ciccozzi, M, Cid, J, Ciofu, O, Cisneros, D, Ciufolini, MG, Clark, C, Clarke, SC, Clayton, R, Clementi, M, Clemons, K, Cloeckaert, Ael, Cloud, J, Coenye, T, Cohen Bacri, S, Cohen, R, Coia, J, Colombo, A, Colson, P, Concerse, P, Cordonnier, C, Cormican, M, Cornaglia, G, Cornely, O, Costa, S, Cots, F, Craxi, A, Creti, R, Crnich, C, Cuenca Estrella, M, Cusi, MG, d'Ettorre, G, da Cruz Lamas, C, Daikos, G, Dannaoui, E, De Barbeyrac, B, De Grazia, S, de Jager, C, de Lamballerie, X, de Marco, F, del Palacio, A, Delpeyroux, F, Denamur, E, Denis, O, Depaquit, J, Deplano, A, Desenclos, J-C, Desjeux, P, Deutch, S, Di Luca, D, Dianzani, F, Diep, B, Diestra, K, Dignani, C, Dimopoulos, G, Divizia, M, Doi, Y, Dornbusch, HJ, Dotis, J, Drancourt, M, Drevinek, P, Dromer, F, Dryden, M, Dubreuil, L, Dubus, J-C, Dumitrescu, O, Dumke, R, DuPont, H, Edelstein, M, Eggimann, P, Eis-Huebinger, A-M, El Atrouni, WI, Entenza, J, Ergonul, O, Espinel-Ingroff, A, Esteban, J, Etienne, J, Fan, X-G, Fenollar, F, Ferrante, P, Ferrieri, P, Ferry, T, Feuchtinger, T, Finegold, S, Fingerle, V, Fitch, M, Fitzgerald, R, Flori, P, Fluit, A, Fontana, R, Fournier, PE, François, M, Francois, P, Freedman, DO, Friedrich, A, Gallego, L, Gallinella, G, Gangneux, J-P, Gannon, V, Garbarg-Chenon, A, Garbino, J, Garnacho-Montero, J, Gatermann, Soeren, Gautret, P, Gentile, G, Gerlich, W, Ghannoum, M, Ghebremedhin, B, Ghigo, E, Giamarellos-Bourboulis, E, Girgis, R, Giske, C, Glupczynski, Y, Gnarpe, J, Gomez-Barrena, E, Gorwitz, RJ, Gosselin, R, Goubau, P, Gould, E, Gradel, K, Gray, J, Gregson, D, Greub, G, Grijalva, CG, Groll, A, Groschup, M, Gutiérrez, J, Hackam, DG, Hall, WA, Hallett, R, Hansen, S, Harbarth, S, Harf-Monteil, C, Hasanjani, Roushan MR, Hasler, P, Hatchette, T, Hauser, P, He, Q, Hedges, A, Helbig, J, Hennequin, C, Herrmann, B, Hezode, C, Higgins, P, Hoesli, I, Hoiby, N, Hope, W, Houvinen, P, Hsu, LY, Huard, R, Humphreys, H, Icardi, M, Imoehl, M, Ivanova, K, Iwamoto, T, Izopet, J, Jackson, Y, Jacobsen, K, Jang, TN, Jasir, A, Jaulhac, B, Jaureguy, F, Jefferies, JM, Jehl, F, Johnstone, J, Joly-Guillou, M-L, Jonas, M, Jones, M, Joukhadar, C, Kahl, B, Kaier, K, Kaiser, L, Kato, H, Katragkou, A, Kearns, A, Kern, W, Kerr, K, Kessin, R, Kibbler, C, Kimberlin, D, Kittang, B, Klaassen, C, Kluytmans, J, Ko, W-C, Koh, W-J, Kostrzewa, M, Kourbeti, I, Krause, R, Krcmery, V, Krizova, P, Kuijper, E, Kullberg, B-J, Kumar, G, Kunin, CM, La Scola, B, Lagging, M, Lagrou, K, Lamagni, T, Landini, P, Landman, D, Larsen, A, Lass-Floerl, C, Laupland, K, Lavigne, JP, Leblebicioglu, H, Lee, B, Lee, CH, Leggat, P, Lehours, P, Leibovici, Lonard, Leon, L, Leonard, N, Leone, M, Lescure, X, Lesprit, P, Levy, PY, Lew, D, Lexau, CA, Li, S-Y, Li, W, Lieberman, D, Lina, B, Lina, G, Lindsay, JA, Livermore, D, Lorente, L, Lortholary, O, Lucet, J-C, Lund, B, Lütticken, R, MacLeod, C, Madhi, S, Maertens, J, Maggi, F, Maiden, M, Maillard, J-Y, Maira-Litran, T, Maltezou, H, Manian, FA, Mantadakis, E, Maragakis, L, Marcelin, A-G, Marchaim, D, Marchetti, O, Marcos, M, Markotic, A, Martina, B, Martínez, J, Martinez, J-L, Marty, F, Maurin, M, McGee, L, Mediannikov, O, Meersseman, W, Megraud, F, Meletiadis, J, Mellmann, A, Meyer, E, Meyer, W, Meylan, P, Michalopoulos, A, Micol, R, Midulla, F, Mikami, Y, Miller, RF, Miragaia, M, Miriagou, V, Mitchell, TJ, Miyakis, S, Mokrousov, I, Monecke, S, Mönkemüller, K, Monno, L, Monod, M, Morales, G, Moriarty, F, Morosini, I, Mortensen, E, Mubarak, K, Mueller, B, Mühlemann, K, Muñoz Bellido, JL, Murray, P, Muscillo, M, Mylotte, J, Naessens, A, Nagy, E, Nahm, MH, Nassif, X, Navarro, D, Navarro, F, Neofytos, D, Nes, I, Ní Eidhin, D, Nicolle, L, Niederman, MS, Nigro, G, Nimmo, G, Nordmann, P, Nougairède, A, Novais, A, Nygard, K, Oliveira, D, Orth, D, Ortiz, JR, Osherov, N, Österblad, M, Ostrosky-Zeichner, L, Pagano, L, Palamara, AT, Pallares, R, Panagopoulou, P, Pandey, P, Panepinto, J, Pappas, G, Parkins, M, Parola, P, Pasqualotto, A, Pasteran, F, Paul, M, Pawlotsky, J-M, Peeters, M, Peixe, L, Pepin, J, Peralta, G, Pereyre, S, Perfect, JR, Petinaki, E, Petric, M, Pettigrew, M, Pfaller, M, Philipp, M, Phillips, G, Pichichero, M, Pierangeli, A, Pierard, D, Pigrau, C, Pilishvili, T, Pinto, F, Pistello, M, Pitout, J, Poirel, L, Poli, G, Poppert, S, Posfay-Barbe, K, Pothier, P, Poxton, I, Poyart, C, Pozzetto, B, Pujol, M, Pulcini, C, Punyadeera, C, Ramirez, M, Ranque, S, Raoult, D, Rasigade, J-P, Re, MC, Reilly, JS, Reinert, R, Renaud, B, Rice, L, Rich, S, Richet, H, Rigouts, L, Riva, E, Rizzo, C, Robotham, J, Rodicio, MR, Rodriguez, J, Rodriguez-Bano, J, Rogier, C, Roilides, E, Rolain, J-M, Rooijakkers, S, Rooney, P, Rossi, F, Rotimi, V, Rottman, M, Roux, V, Ruhe, J, Russo, G, Sadowy, E, Sagel, U, Said, SI, Saijo, M, Sak, B, Sa-Leao, R, Sanders, EAM, Sanguinetti, M, Sarrazin, C, Savelkoul, P, Scheifele, D, Schmidt, W-P, Schønheyder, H, Schönrich, G, Schrenzel, J, Schubert, S, Schwarz, K, Schwarz, S, Sefton, A, Segondy, M, Seifert, H, Seng, P, Senneville, E, Sexton, D, Shafer, RW, Shalit, I, Shankar, N, Shata, TM, Shields, J, Sibley, C, Sicinschi, L, Siljander, T, Simitsopoulou, M, Simoons-Smit, AM, Sissoko, D, Sjögren, J, Skiada, A, Skoczynska, A, Skov, R, Slack, M, Sogaard, M, Sola, C, Soriano, A, Sotto, A, Sougakoff, W, Souli, M, Spelberg, B, Spelman, D, Spiliopoulou, I, Springer, B, Stefani, S, Stein, A, Steinbach, WJ, Steinbakk, M, Strakova, L, Strenger, V, Sturm, P, Sullivan, P, Sutton, D, Symmons, D, Tacconelli, E, Tamalet, C, Tang, JW, Tang, Y-W, Tattevin, P, Thibault, V, Thomsen, RW, Thuny, F, Tong, S, Torres, C, Townsend, R, Tristan, A, Trouillet, J-L, Tsai, H-C, Tsitsopoulos, P, Tuerlinckx, D, Tulkens, P, Tumbarello, M, Tureen, J, Turnidge, JD, Turriziani, O, Tutuian, R, Uçkay, I, Upton, M, Vabret, A, Vamvakas, EC, van den Boom, D, Van Eldere, J, van Leeuwen, W, van Strijp, J, Van Veen, S, Vandamme, P, Vandenesch, F, Vayssier, M, Velin, D, Venditti, M, Venter, M, Venuti, A, Vergnaud, G, Verheij, T, Verhofstede, C, Viscoli, C, Vizza, CD, Vogel, U, Waller, A, Wang, YF, Warn, P, Warris, A, Wauters, G, Weidmann, M, Weill, F-X, Weinberger, M, Welch, D, Wellinghausen, N, Wheat, J, Widmer, A, Wild, F, Willems, R, Willinger, B, Winstanley, C, Witte, W, Wolff, M, Wong, F, Wootton, M, Wyllie, D, Xu, W, Yamamoto, S, Yaron, S, Yildirim, I, Zaoutis, T, Zazzi, M, Zbinden, R, Zehender, Gianguglielmo G, Zemlickova, H, Zerbini, ML, Zhang, L, Zhang, Y, Zhao, Y-D, Zhu, Z, and Zimmerli, W

Published
2011
Full Text
View/download PDF

42. Double Infection with Leishmania tropica and L. Major in an Hiv patient controlled with high doses of amphotericin B

Author

Balushi, A.A. (Asma Al), Khamis, F. (Faryal), Klaassen, C.H. (Corné), Gangneux, J.-P. (Jean-Pierre), Hellemond, J.J. (Jaap) van, Petersen, E. (Eskild), Balushi, A.A. (Asma Al), Khamis, F. (Faryal), Klaassen, C.H. (Corné), Gangneux, J.-P. (Jean-Pierre), Hellemond, J.J. (Jaap) van, and Petersen, E. (Eskild)

Abstract

We present a unique case of disseminated Leishmaniasis in an HIV patient. Two different Leishmania species were identified by genomic sequencing in both bone marrow and skin. The Leishmania infection could be suppressed but not cured, despite a high dose of amphotericin B of nearly 65 g over more than 6 years.

Published
2018
Full Text
View/download PDF

43. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

Author

Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Floerl, C., Lewis, R. E., Munoz, P., Verweij, P. E., Warris, A., Ader, F., Akova, M., Arendrup, M. C., Barnes, R. A., Beigelman-Aubry, C., Blot, S., Bouza, E., Bruggemann, R. J. M., Buchheidt, D., Cadranel, J., Castagnola, E., Chakrabarti, A., Cuenca-Estrella, M., Dimopoulos, G., Fortun, J., Gangneux, J. -P., Garbino, J., Heinz, W. J., Herbrecht, R., Heussel, C. P., Kibbler, C. C., Klimko, N., Kullberg, B. J., Lange, C., Lehrnbecher, T., Loeffler, J., Lortholary, O., Maertens, J., Marchetti, O., Meis, J. F., Pagano, L., Ribaud, P., Richardson, M., Roilides, E., Ruhnke, M., Sanguinetti, M., Sheppard, D. C., Sinko, J., Skiada, A., Vehreschild, M. J. G. T., Viscoli, C., Cornely, O. A., Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Floerl, C., Lewis, R. E., Munoz, P., Verweij, P. E., Warris, A., Ader, F., Akova, M., Arendrup, M. C., Barnes, R. A., Beigelman-Aubry, C., Blot, S., Bouza, E., Bruggemann, R. J. M., Buchheidt, D., Cadranel, J., Castagnola, E., Chakrabarti, A., Cuenca-Estrella, M., Dimopoulos, G., Fortun, J., Gangneux, J. -P., Garbino, J., Heinz, W. J., Herbrecht, R., Heussel, C. P., Kibbler, C. C., Klimko, N., Kullberg, B. J., Lange, C., Lehrnbecher, T., Loeffler, J., Lortholary, O., Maertens, J., Marchetti, O., Meis, J. F., Pagano, L., Ribaud, P., Richardson, M., Roilides, E., Ruhnke, M., Sanguinetti, M., Sheppard, D. C., Sinko, J., Skiada, A., Vehreschild, M. J. G. T., Viscoli, C., and Cornely, O. A.

Abstract

The European Society for Clinical Microbiology and Infectious Diseases, the European Confederation of Medical Mycology and the European Respiratory Society Joint Clinical Guidelines focus on diagnosis and management of aspergillosis. Of the numerous recommendations, a few are summarized here. Chest computed tomography as well as bronchoscopy with bronchoalveolar lavage (BAL) in patients with suspicion of pulmonary invasive aspergillosis (IA) are strongly recommended. For diagnosis, direct micro-scopy, preferably using optical brighteners, histopathology and culture are strongly recommended. Serum and BAL galactomannan measures are recommended as markers for the diagnosis of IA. PCR should be considered in conjunction with other diagnostic tests. Pathogen identification to species complex level is strongly recommended for all clinically relevant Aspergillus isolates; antifungal susceptibility testing should be performed in patients with invasive disease in regions with resistance found in contemporary surveillance programmes. Isavuconazole and voriconazole are the preferred agents for first-line treatment of pulmonary IA, whereas liposomal amphotericin B is moderately supported. Combinations of antifungals as primary treatment options are not recommended. Therapeutic drug monitoring is strongly recommended for patients receiving posaconazole suspension or any form of voriconazole for IA treatment, and in refractory disease, where a personalized approach considering reversal of predisposing factors, switching drug class and surgical intervention is also strongly recommended. Primary prophylaxis with posaconazole is strongly recommended in patients with acutemyelogenous leukaemia ormyelodysplastic syndrome receiving induction chemotherapy. Secondary prophylaxis is strongly recommended in high-risk patients. We strongly recommend treatment duration based on clinical improvement, degree of immunosuppression and response on imaging. (C) 2018 European Society of Clinical M

Published
2018

46. Travelers With Cutaneous Leishmaniasis Cured Without Systemic Therapy

Author

Morizot, G., Kendjo, E., Mouri, O., Thellier, M., Pérignon, A., Foulet, F., Cordoliani, F., Bourrat, E., Laffitte, E., Alcaraz, I., Bodak, N., Ravel, C., Vray, M., Grogl, M., Mazier, D., Caumes, E., Lachaud, L., Buffet, P. A., El Samad, Y., Salle, V., Gounod, N., Dallot, A., Belot, G., Pelletier-Cunat, S., Belon, M., Verdon, R., Rogeaux, O., Grossetête, G., Lesens, O., Clabaut, A., Maus, E., Jouy, L., Gener, G., Perrin, P., Roch, N., Herve, A., Le Duc, D., Cuchet, E., Maubon, D., Hillion, B., Menot, E., Guillemot, F., Beneton-Benhard, N., Celerier, P., Dupuis De Fonclare, A. L., Carre, D., Bourgeois, A., Marty, P., Pomares, C., Meunier, L., Abergel, H., Timsit, F., Amoric, J. C., Busquet, P., Karam, S., Moisson, Y. F., Mouly, F., Ortoli, J. C., Consigny, P. H., Jouan, M., Caby, F., Datry, A., Hochedez, P., Rozembaum, F., Dumortier, C., Ancelle, T., Dupin, N., Paugam, A., Ranque, B., Bougnoux, M. E., Canestri, A., Galezowsky, M. F., Hadj Rabia, S., Hamel, D., Schneider, P., Wolter-Desfosses, M., Janier, M., Baccard, M., Bezier, M., Broissin, M., Colin De Verdiere, N., Durupt, F., Hope Rapp, E., Juillard, C., Levy, A., Moraillon, I., Petit, A., Regner, S., Barthelme, D., Tamarin, J. M., Begon, E., Strady, C., Gangneux, J. P., Carpentier, O., Mechai, F., Kieffer, C., Dellestable, P., and Rebauder, S.

Abstract

Guidelines recommend wound care and/or local therapy as first-line treatment for cutaneous leishmaniasis. An analysis of a referral treatment program in 135 travelers showed that this approach was feasible in 62% of patients, with positive outcome in 83% of evaluable patients

Published
2017

47. Impact of early azole therapy on chronic colonisation with Aspergillus fumigatus during cystic fibrosis

Author

Gangneux, J.-P.

Abstract

Impact of early azole therapy on chronic colonisation with Aspergillus fumigatus during cystic fibrosisObjectives. Early azole therapy during cystic fibrosis (CF) remains debated : when to start ? with which azole ? when to stop ? The ATCF (Antifungal Therapy during Cystic Fibrosis) is an exploratory longitudinal phase III study with the following objectives :-tthe primary objective was to assess the effect of azole therapy on the negativation of sputum cultures for Aspergillus on 2 consecutive samples.-tSecondary objectives were to compare the course and outcome of FEV1, clinical signs and quality of life, the impact on co-prescription of antibiotic courses and steroid therapies, the speed of negativation of sputum cultures for Aspergillus, the efficacy of treatments on outcome of other diagnostic criteria (Aspergillus precipiting IgG, total and specific IgE, eosinophil counts), and safety profiles of the azoles.Methods. The ATCF study followed 11 patients presenting with a chronic colonisation with A. fumigatus and randomized to receive an early azole therapy for 4 to 6 months in a phase III study. Treatments evaluated were itraconazole (ITRA) oral solution or voriconazole (VORI) oral suspension at the following regimens: 2x200 mg/day for patients > 40kg and 2x100 mg/day for patients

Published
2017

48. A National Survey On Tinea Capitis In France : Epidemiology And Diagnostic Procedures

Author

Gangneux, J.-P.

Abstract

Objectives. The French Society for Medical Mycology (SFMM=Sociu00e9tu00e9 Franu00e7aise de Mycologie Mu00e9dicale) conducted a national survey on tinea capitis in France with the aim to describe the epidemiology and the methods of diagnosis.Methods. Thirty five laboratories (26 University hospitals, 6 general hospitals and 3 private labs) answered to the survey and reported their cases during a 3-year period (2014 -2016). For each case, sex, age, and species identification were collected. Diagnotic methods were also recorded: sampling and tools, cultures (medium, temperature, duration) and identification methods for dermatophytes.Results. A total of 2,369 cases were recorded. The 3 anthropophilic species Trichophyton soudanense/T. violaceum, T. tonsurans and Microsporum audouinii/langeronii were predominant, and accounted for 33%, 31% and 19% of cases, respectively. By contrast, zoophilic species such as M. canis (10%) were less prevalent. Males were slightly over-represented (59% of cases) and the prominent class of age was 5-10 years (45%), but globally 86% of patients were aged between 0 and 10 years. Sampling methods were mainly scraping (33/36 centers) and swab collection (20/36), most often guided by the Wood light that was available in 72% of centers. Direct examination was mostly realized with chlorazole black or chloral-lactophenol, and culture relied mainly on the combination of Sabouraud medium + Sabouraud-actidione medium, and rare others media for particular situations: Malt and Borelli media to help fructification, Brain-Heart-Infusion to detect T. verrucosum, etc. All labs used macrocopic and microscopic examinations of the cultures to identify dermatophytes, and 39% and 36% of labs declared to use also more recent tools such as PCR and MALDI-TOF mass spectrometry, respectively.Conclusion. A consequent number of tinea capitis is still diagnosed in France. Autochtonous but also migrant populations account for more than 800 cases/year. Anthropophilic species are prominant with T. soudanense/T. violaceum and T. tonsurans that are mainly isolated. Sampling and identification methods are diverse and should be homogenised. New identification methods such as mass spectrometry and molecular biology are now used in more than 1/3 of the labs that answered to the survey.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results